- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | HCW Biologics receives $7M upfront fee from China licensee | 1 | Investing.com | ||
| 17.03. | HCW Biologics erhält 7 Millionen US-Dollar Vorauszahlung von Lizenznehmer aus China | 10 | Investing.com Deutsch | ||
| 17.03. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | HCW Biologics Inc.: HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic | 1 | GlobeNewswire (USA) | ||
| 16.03. | HCW Biologics' compound shows promise in CAR-T cell production | 5 | Investing.com | ||
| 16.03. | HCW Biologics Inc.: HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances | 470 | GlobeNewswire (Europe) | Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactured... ► Artikel lesen | |
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 02.03. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.02. | HCW Biologics Inc.: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules | 5 | GlobeNewswire (USA) | ||
| 17.02. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.02. | HCW Biologics enters $7 million licensing deal with China-based Trimmune | 11 | Investing.com | ||
| 13.02. | HCW Biologics: 7-Millionen-Dollar-Lizenzdeal mit Partner in China | 1 | Investing.com Deutsch | ||
| 13.02. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | HCW Biologics Inc.: HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune | 1.647 | GlobeNewswire (Europe) | HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with... ► Artikel lesen | |
| 11.02. | HCW Biologics Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 09.01. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 31.12.25 | HCW Biologics ergreift Maßnahmen zur Wiedererlangung der Nasdaq-Konformität | 1 | Investing.com Deutsch | ||
| 31.12.25 | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | HCW Biologics secures $4 million through warrant exercise agreement | 1 | Investing.com | ||
| 19.11.25 | HCW Biologics Inc.: HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 19.11.25 | HCW Biologics schließt geänderte Lizenzvereinbarung mit Beijing Trimmune Biotech ab | 1 | Investing.com Deutsch |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | ||
| QIAGEN | 34,540 | +1,75 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,510 | -0,68 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| RELAY THERAPEUTICS | 9,350 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BULLFROG AI | 1,070 | 0,00 % | Bullfrog AI stock offers a rare opportunity for investors to take profit | ||
| ALUMIS | 20,130 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 74,25 | -0,07 % | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,165 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,940 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| NUVALENT | 96,81 | +0,16 % | Wells Fargo stuft Nuvalent wegen hohem Medikamentenpotenzial mit "Overweight" ein | ||
| ARCELLX | 114,76 | +0,17 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| CG ONCOLOGY | 63,90 | -1,19 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| ARRIVENT BIOPHARMA | 21,010 | -1,82 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,650 | -5,78 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| EVOTEC | 4,270 | -0,81 % | Evotec streicht 800 Stellen - und trotzdem sehen Analysten 100% Kurspotenzial | 800 Stellen weg, Kosten explodiert, Gewinne verschoben - Evotec steckt tief in der Krise. Doch Analysten sehen mehr als 100% Kurspotenzial. Was steckt hinter dem Widerspruch? Rund 800 Stellen werden... ► Artikel lesen |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,353 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.